# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 16, "Horm Metab Res .", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasJournal> \"Horm Metab Res .\"."
76401, PublicationYear, 17, 21, "2014", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasPublicationYear> \"2014\"."
17, Title, 108, 219, "Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasTitle> \"Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .\"."
79622, Colesevelam, 131, 142, "colesevelam", "", 
10, Pioglitazone, 163, 175, "pioglitazone", "", 
13, Type2Diabetes, 193, 217, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
18, Author, 220, 232, "Rosenstock J", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Rosenstock J\"."
19, Author, 241, 250, "Truitt KE", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Truitt KE\"."
20, Author, 259, 272, "Baz - Hecht M", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Baz - Hecht M\"."
21, Author, 281, 288, "Ford DM", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Ford DM\"."
22, Author, 297, 302, "Tao B", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Tao B\"."
23, Author, 311, 318, "Chou HS", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasAuthor> \"Chou HS\"."
24, USA, 423, 426, "USA", "", "<http://ctro/data#Population_62136> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
25, USA, 485, 488, "USA", "", 
79623, Colesevelam, 491, 502, "Colesevelam", "", 
125, ObjectiveDescription, 491, 645, "Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens .", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasObjectiveDescription> \"Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens .\"."
14, Type2Diabetes, 546, 561, "type 2 diabetes", "", 
26, Metformin, 585, 594, "metformin", "", 
27, Sulfonylureas, 599, 611, "sulfonylurea", "", 
28, Insulin, 619, 626, "insulin", "", 
30, ObjectiveDescription, 646, 735, "We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasObjectiveDescription> \"We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .\"."
79625, Colesevelam, 659, 670, "colesevelam", "", 
29, Pioglitazone, 705, 717, "pioglitazone", "", 
31, Duration, 741, 750, "24 - week", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasCTduration> \"24 - week\"."
32, Multicenter, 751, 762, "multicenter", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
33, DoubleBlind, 765, 779, "double - blind", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
34, Randomized, 782, 792, "randomized", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
35, Placebo, 795, 802, "placebo", "", 
76408, Precondition, 831, 894, "adults with type 2 diabetes who had suboptimal glycemic control", "", "<http://ctro/data#Population_62136> <http://ctro/data#hasPrecondition> \"adults with type 2 diabetes who had suboptimal glycemic control\". <http://ctro/data#Population_62136> <http://ctro/data#hasPrecondition> \"on pioglitazone\". <http://ctro/data#Population_62136> <http://ctro/data#hasPrecondition> \"with or without 1 - 2 other oral antidiabetes medications\"."
15, Type2Diabetes, 843, 858, "type 2 diabetes", "", 
40, HbA1c, 897, 902, "HbA1c", "", 
79789, Millimoles_per_mole, 908, 918, "mmol / mol", "", 
43, Percentage, 927, 928, "%", "", 
79790, Millimoles_per_mole, 940, 950, "mmol / mol", "", 
44, Percentage, 959, 960, "%", "", 
76408, Precondition, 965, 980, "on pioglitazone", "", 
45, Pioglitazone, 968, 980, "pioglitazone", "", 
47, DoseValue, 983, 985, "30", "", 
48, DoseValue, 989, 991, "45", "", 
49, mg, 992, 994, "mg", "", 
76408, Precondition, 997, 1054, "with or without 1 - 2 other oral antidiabetes medications", "", 
46, OralAntidiabeticAgent, 1025, 1054, "oral antidiabetes medications", "", 
51, Randomized, 1071, 1081, "randomized", "", 
79627, Colesevelam, 1085, 1096, "colesevelam", "", "<http://ctro/data#Medication_62180> <http://ctro/data#hasDrug> <http://ctro/data#Colesevelam>."
52, DoseValue, 1097, 1102, "3 . 8", "", "<http://ctro/data#Medication_62180> <http://ctro/data#hasDoseValue> \"3 . 8\"."
53, Gram, 1103, 1104, "g", "", "<http://ctro/data#Medication_62180> <http://ctro/data#hasDoseValue> \"3 . 8\"."
100520, Frequency, 1107, 1110, "day", "", "<http://ctro/data#Intervention_62162> <http://ctro/data#hasFrequency> \"day\"."
55, NumberPatientsArm, 1117, 1120, "280", "", "<http://ctro/data#Arm_62144> <http://ctro/data#hasNumberPatientsArm> \"280\"."
36, Placebo, 1126, 1133, "placebo", "", "<http://ctro/data#Medication_62187> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
56, NumberPatientsArm, 1140, 1143, "282", "", "<http://ctro/data#Arm_62153> <http://ctro/data#hasNumberPatientsArm> \"282\"."
11, Pioglitazone, 1164, 1176, "pioglitazone", "", 
148, Mean, 1225, 1229, "mean", "", 
57, HbA1c, 1240, 1245, "HbA1c", "", 
58, TimePoint, 1251, 1259, "baseline", "", 
59, TimePoint, 1263, 1270, "Week 24", "", 
60, FastingPlasmaGlucose, 1328, 1350, "fasting plasma glucose", "", 
61, EndPointDescription, 1386, 1399, "lipid profile", "", 
62, EndPointDescription, 1430, 1452, "lipid particle profile", "", 
79630, Colesevelam, 1493, 1504, "Colesevelam", "", 
63, HbA1c, 1515, 1520, "HbA1c", "", "<http://ctro/data#Endpoint_62229> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
64, LeastSquaresMean, 1523, 1543, "least - squares mean", "", "<http://ctro/data#Endpoint_62229> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
65, DiffGroupAbsValue, 1567, 1574, "- 3 . 5", "", 
79793, Millimoles_per_mole, 1575, 1585, "mmol / mol", "", "<http://ctro/data#Endpoint_62229> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_mole>."
68, DiffGroupAbsValue, 1588, 1596, "- 0 . 32", "", "<http://ctro/data#DiffBetweenGroups_62347> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 32\"."
69, Percentage, 1597, 1598, "%", "", 
70, PvalueDiff, 1603, 1614, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_62347> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
72, FastingPlasmaGlucose, 1621, 1643, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_62288> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
66, DiffGroupAbsValue, 1646, 1654, "- 14 . 7", "", "<http://ctro/data#DiffBetweenGroups_62356> <http://ctro/data#hasDiffGroupAbsValue> \"- 14 . 7\"."
73, Mg_per_deciliter, 1655, 1662, "mg / dl", "", "<http://ctro/data#Endpoint_62288> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Mg_per_deciliter>."
71, PvalueDiff, 1665, 1676, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_62356> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
37, Placebo, 1684, 1691, "placebo", "", 
74, TimePoint, 1695, 1702, "Week 24", "", "<http://ctro/data#Outcome_62234> <http://ctro/data#hasTimePoint> \"Week 24\". <http://ctro/data#Outcome_62261> <http://ctro/data#hasTimePoint> \"Week 24\". <http://ctro/data#Outcome_62293> <http://ctro/data#hasTimePoint> \"Week 24\". <http://ctro/data#Outcome_62320> <http://ctro/data#hasTimePoint> \"Week 24\"."
79633, Colesevelam, 1729, 1740, "colesevelam", "", 
38, Placebo, 1746, 1753, "placebo", "", 
75, HbA1c_target, 1763, 1809, "HbA1c reduction â‰¥ 7 . 7 mmol / mol ( 0 . 7 % )", "", "<http://ctro/data#Endpoint_62365> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
79791, Millimoles_per_mole, 1787, 1797, "mmol / mol", "", 
177, Percentage, 1806, 1807, "%", "", 
77, PercentageAffected, 1812, 1814, "40", "", "<http://ctro/data#Outcome_62375> <http://ctro/data#hasPercentageAffected> \"40\"."
78, PercentageAffected, 1822, 1824, "25", "", "<http://ctro/data#Outcome_62402> <http://ctro/data#hasPercentageAffected> \"25\"."
81, PvalueDiff, 1829, 1840, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_62483> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
76, HbA1c_target, 1846, 1879, "HbA1c < 53 mmol / mol ( 7 . 0 % )", "", "<http://ctro/data#Endpoint_62370> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
79792, Millimoles_per_mole, 1857, 1867, "mmol / mol", "", 
182, Percentage, 1876, 1877, "%", "", 
79, PercentageAffected, 1882, 1884, "21", "", "<http://ctro/data#Outcome_62429> <http://ctro/data#hasPercentageAffected> \"21\"."
80, PercentageAffected, 1892, 1894, "13", "", "<http://ctro/data#Outcome_62456> <http://ctro/data#hasPercentageAffected> \"13\"."
82, PvalueDiff, 1899, 1910, "p = 0 . 012", "", "<http://ctro/data#DiffBetweenGroups_62492> <http://ctro/data#hasPvalueDiff> \"p = 0 . 012\"."
79635, Colesevelam, 1915, 1926, "Colesevelam", "", 
83, EndPointDescription, 1948, 1959, "cholesterol", "", "<http://ctro/data#EndPointDescription_62502> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62501> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62502>."
200, Mean, 1962, 1966, "mean", "", "<http://ctro/data#Mean_62503> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_62501> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_62503>."
90, DiffGroupRelValue, 1990, 1997, "- 6 . 5", "", "<http://ctro/data#DiffBetweenGroups_62914> <http://ctro/data#hasDiffGroupRelValue> \"- 6 . 5\"."
84, EndPointDescription, 2004, 2021, "LDL - cholesterol", "", "<http://ctro/data#EndPointDescription_62507> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62506> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62507>."
91, DiffGroupRelValue, 2024, 2032, "- 16 . 4", "", "<http://ctro/data#DiffBetweenGroups_62923> <http://ctro/data#hasDiffGroupRelValue> \"- 16 . 4\"."
85, EndPointDescription, 2039, 2062, "non - HDL - cholesterol", "", "<http://ctro/data#EndPointDescription_62512> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62511> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62512>."
92, DiffGroupRelValue, 2065, 2072, "- 9 . 8", "", "<http://ctro/data#DiffBetweenGroups_62932> <http://ctro/data#hasDiffGroupRelValue> \"- 9 . 8\"."
86, EndPointDescription, 2079, 2095, "apolipoprotein B", "", "<http://ctro/data#EndPointDescription_62517> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62516> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62517>."
93, DiffGroupRelValue, 2098, 2105, "- 8 . 8", "", "<http://ctro/data#DiffBetweenGroups_62941> <http://ctro/data#hasDiffGroupRelValue> \"- 8 . 8\"."
87, EndPointDescription, 2122, 2148, "LDL particle concentration", "", "<http://ctro/data#EndPointDescription_62522> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62521> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62522>."
88, EndPointDescription, 2165, 2182, "apolipoprotein A1", "", "<http://ctro/data#EndPointDescription_62527> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62526> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62527>."
94, DiffGroupRelValue, 2185, 2192, "+ 3 . 4", "", "<http://ctro/data#DiffBetweenGroups_62959> <http://ctro/data#hasDiffGroupRelValue> \"+ 3 . 4\"."
89, EndPointDescription, 2201, 2214, "triglycerides", "", "<http://ctro/data#EndPointDescription_62532> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62531> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62532>."
95, DiffGroupRelValue, 2247, 2255, "+ 11 . 3", "", "<http://ctro/data#DiffBetweenGroups_62968> <http://ctro/data#hasDiffGroupRelValue> \"+ 11 . 3\"."
39, Placebo, 2265, 2272, "placebo", "", 
96, PvalueDiff, 2279, 2290, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_62914> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62923> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62932> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62941> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62950> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62959> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_62968> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
76412, ObservedResult, 2295, 2331, "There were no serious drug - related", "", "<http://ctro/data#Outcome_62982> <http://ctro/data#hasObservedResult> \"There were no serious drug - related\". <http://ctro/data#Outcome_63009> <http://ctro/data#hasObservedResult> \"There were no serious drug - related\"."
97, EndPointDescription, 2332, 2346, "adverse events", "", "<http://ctro/data#EndPointDescription_62978> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_62977> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_62978>."
98, EndPointDescription, 2369, 2383, "adverse events", "", 
101, ConclusionComment, 2408, 2601, "In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .", "", "<http://ctro/data#ClinicalTrial_62120> <http://ctro/data#hasConclusionComment> \"In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .\"."
16, Type2Diabetes, 2425, 2440, "type 2 diabetes", "", 
12, Pioglitazone, 2470, 2482, "pioglitazone", "", 
79637, Colesevelam, 2510, 2521, "colesevelam", "", 
102, PMID, 2742, 2750, "25054436", "", "<http://ctro/data#Publication_62113> <http://ctro/data#hasPMID> \"25054436\"."
